Advertisement

Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review

  • G. F. P. AleixoEmail author
  • G. R. Williams
  • K. A. Nyrop
  • H. B. Muss
  • S. S. Shachar
Review
  • 54 Downloads

Abstract

Purpose

Breast cancer is the most common cancer and leading cause of cancer death in women. Body composition parameters, especially those related to muscle, have become a growing focus of cancer research. In this review, we summarize the literature on breast cancer and muscle parameters as well as combine their outcomes for overall survival (OS), time to tumor progression (TTP), and chemotherapy toxicity in a meta-analysis.

Methods

A systematic search of the literature for randomized controlled trials and observational studies was conducted on MEDLINE, Cochrane CENTRAL, and EMBASE through May 1, 2019. Two reviewers independently searched and selected. Meta-analysis was conducted using a random-effects model. The risk of bias was evaluated using the Newcastle–Ottawa quality assessment for cohorts and GRADE summary of findings tool from Cochrane.

Results

A total of 754 articles were screened from which 6 articles and one abstract were selected. Using skeletal muscle index (SMI), patients classified as sarcopenic had a 68% greater mortality risk compared to non-sarcopenic patients (HR 1.68 95% CI 1.09–2.59, 5 studies) (p = .02) (i2 = 70%). Low muscle density was not predictive of OS (HR 1.44 95% CI 0.77–2.68, 2 studies) (p = .25) (i2 = 87%). Patients with sarcopenia (56%) had more grade 3–5 toxicity compared to non-sarcopenic (25%) (RR 2.17 95% CI 1.4–3.34, 3 studies) (p = .0005) (i2 = 0%). TTP was nearly 71 days longer in advanced/metastatic patients classified as non-sarcopenic compared to patients with sarcopenia (MD − 70.75 95% CI − 122.32 to − 19.18) (p = .007) (i2 = 0%).

Conclusion

Our synthesis of the literature shows that patients with sarcopenia have more severe chemotherapy toxicity as well as shorter OS and TTP, and that low muscle density is prognostic of OS for women with metastatic breast cancer. Our findings suggest that in clinical practice, body composition assessment is valuable as a prognostic parameter in breast cancer.

Keywords

Breast cancer Sarcopenia Myosteatosis Muscle measures 

Abbreviations

SMI

Skeletal muscle index

SMD

Skeletal muscle density

SMG

Skeletal muscle gauge

VAT

Visceral adipose tissue

SAT

Subcutaneous adipose tissue

CT

Computer tomography

MRI

Magnetic resonance imaging

DEXA

Dual X-ray absorptiometry

BIA

Bioelectrical impedance analysis

Notes

Acknowledgements

We thank for the help and guidance on our search from the University of North Carolina Health Sciences Library.

Compliance with ethical standards

Conflict of interest

The authors declare they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

This study did not entail direct contact with humans and therefore did not entail obtaining informed consent.

Supplementary material

10549_2019_5352_MOESM1_ESM.docx (13 kb)
Supplementary material 1 (DOCX 13 kb)

References

  1. 1.
  2. 2.
    Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30CrossRefGoogle Scholar
  3. 3.
    Torre LA, Siegel RL, Ward EM et al (2016) Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomark Prev 25:16–27CrossRefGoogle Scholar
  4. 4.
    Veronesi U, Marubini E, Del Vecchio M et al (1995) Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 87:19–27CrossRefGoogle Scholar
  5. 5.
    Gobbini E, Ezzalfani M, Dieras V et al (2018) Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur J Cancer 96:17–24CrossRefGoogle Scholar
  6. 6.
    Rosenberg IH (1997) Sarcopenia: origins and clinical relevance. J Nutr 127:990S–991SCrossRefGoogle Scholar
  7. 7.
    Williams GR, Rier HN, McDonald A et al (2019) Sarcopenia & aging in cancer. J Geriatr Oncol 10:374–377CrossRefGoogle Scholar
  8. 8.
    Mintziras I, Miligkos M, Wachter S et al (2018) Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer: systematic review and meta-analysis. Int J Surg 59:19–26CrossRefGoogle Scholar
  9. 9.
    Boshier PR, Heneghan R, Markar SR et al (2018) Assessment of body composition and sarcopenia in patients with esophageal cancer: a systematic review and meta-analysis. Dis Esophagus 1:1.  https://doi.org/10.1093/dote/doy047 CrossRefGoogle Scholar
  10. 10.
    Kamarajah SK, Bundred J, Tan BHL (2019) Body composition assessment and sarcopenia in patients with gastric cancer: a systematic review and meta-analysis. Gastric Cancer 22:10–22CrossRefGoogle Scholar
  11. 11.
    Sun G, Li Y, Peng Y et al (2018) Can sarcopenia be a predictor of prognosis for patients with non-metastatic colorectal cancer? A systematic review and meta-analysis. Int J Colorectal Dis 33:1419–1427CrossRefGoogle Scholar
  12. 12.
    Deng HY, Hou L, Zha P et al (2019) Sarcopenia is an independent unfavorable prognostic factor of non-small cell lung cancer after surgical resection: a comprehensive systematic review and meta-analysis. Eur J Surg Oncol 45:728–735CrossRefGoogle Scholar
  13. 13.
    Williams GR, Deal AM, Muss HB et al (2017) Skeletal muscle measures and physical function in older adults with cancer: sarcopenia or myopenia? Oncotarget 8:33658–33665Google Scholar
  14. 14.
    Kroenke CH, Prado CM, Meyerhardt JA et al (2018) Muscle radiodensity and mortality in patients with colorectal cancer. Cancer 124:3008–3015CrossRefGoogle Scholar
  15. 15.
    Martin L, Birdsell L, Macdonald N et al (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31:1539–1547CrossRefGoogle Scholar
  16. 16.
    Akahori T, Sho M, Kinoshita S et al (2015) prognostic significance of muscle attenuation in pancreatic cancer patients treated with neoadjuvant chemoradiotherapy. World J Surg 39:2975–2982CrossRefGoogle Scholar
  17. 17.
    Aust S, Knogler T, Pils D et al (2015) Skeletal muscle depletion and markers for cancer Cachexia are strong prognostic factors in epithelial ovarian cancer. PLoS ONE 10:e0140403CrossRefGoogle Scholar
  18. 18.
    Centre for Reviews and Dissemination (CRD): PROSPERO: internation prospective register for systematic reviews, University of York, UK, 2019Google Scholar
  19. 19.
    Schardt C, Adams MB, Owens T et al (2007) Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak 7:16CrossRefGoogle Scholar
  20. 20.
    Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560CrossRefGoogle Scholar
  21. 21.
    Polus S, Pieper D, Burns J et al (2017) Heterogeneity in application, design, and analysis characteristics was found for controlled before-after and interrupted time series studies included in Cochrane reviews. J Clin Epidemiol 91:56–69CrossRefGoogle Scholar
  22. 22.
    Higgins JP, Altman DG, Gotzsche PC et al (2011) The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928CrossRefGoogle Scholar
  23. 23.
    Margulis AV, Pladevall M, Riera-Guardia N et al (2014) Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol 6:359–368CrossRefGoogle Scholar
  24. 24.
    von Elm E, Altman DG, Egger M et al (2014) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 12:1495–1499CrossRefGoogle Scholar
  25. 25.
    Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62:1006–1012CrossRefGoogle Scholar
  26. 26.
    Blauwhoff-Buskermolen S, Langius JAE, Becker A et al (2017) The influence of different muscle mass measurements on the diagnosis of cancer cachexia. J Cachexia Sarcopenia Muscle 8:615–622CrossRefGoogle Scholar
  27. 27.
    Del Fabbro E, Parsons H, Warneke CL et al (2012) The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist 17:1240–1245CrossRefGoogle Scholar
  28. 28.
    Mazzuca F, Onesti CE, Roberto M et al (2018) Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines. Oncotarget 9:25714–25722CrossRefGoogle Scholar
  29. 29.
    Shachar SS, Deal AM, Weinberg M et al (2017) Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy. Clin Cancer Res 23:658–665CrossRefGoogle Scholar
  30. 30.
    Sheean P, Gomez-Perez S, Joyce C et al (2019) Body composition, serum biomarkers of inflammation and quality of life in clinically stable women with estrogen receptor positive metastatic breast cancer. Nutr Cancer 71:981–991CrossRefGoogle Scholar
  31. 31.
    Song EJ, Lee CW, Jung SY et al (2018) Prognostic impact of skeletal muscle volume derived from cross-sectional computed tomography images in breast cancer. Breast Cancer Res Treat 172:425–436CrossRefGoogle Scholar
  32. 32.
    Versteeg KS, Blauwhoff-Buskermolen S, Buffart LM et al (2018) Higher muscle strength is associated with prolonged survival in older patients with advanced cancer. Oncologist 23:580–585CrossRefGoogle Scholar
  33. 33.
    Weinberg MS, Shachar SS, Muss HB et al (2018) Beyond sarcopenia: characterization and integration of skeletal muscle quantity and radiodensity in a curable breast cancer population. Breast J 24:278–284CrossRefGoogle Scholar
  34. 34.
    Rossi F, Valdora F, Barabino E et al (2019) Muscle mass estimation on breast magnetic resonance imaging in breast cancer patients: comparison between psoas muscle area on computer tomography and pectoralis muscle area on MRI. Eur Radiol 29:494–500CrossRefGoogle Scholar
  35. 35.
    Caan BJ, Cespedes Feliciano EM, Prado CM et al (2018) Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol 4:798–804CrossRefGoogle Scholar
  36. 36.
    Deluche E, Leobon S, Desport JC et al (2018) Impact of body composition on outcome in patients with early breast cancer. Support Care Cancer 26:861–868CrossRefGoogle Scholar
  37. 37.
    Rier HN, Jager A, Sleijfer S et al (2017) Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. Breast 31:9–15CrossRefGoogle Scholar
  38. 38.
    Villasenor A, Ballard-Barbash R, Baumgartner K et al (2012) Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. J Cancer Surviv 6:398–406CrossRefGoogle Scholar
  39. 39.
    Prado CM, Baracos VE, McCargar LJ et al (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15:2920–2926CrossRefGoogle Scholar
  40. 40.
    Lee HJ, Kim HS, Kim WY et al (2019) Sarcopena as a predicting factors for chemotherapy in advanced breast cancer patients. Eur J Surg Oncol 45:e31CrossRefGoogle Scholar
  41. 41.
    Rossi FVF, Bignotti B, Torri L, Succio G, Tagniafico AS (2019) Evaluation of body Computer Tomography-determined sarcopenia in breast cancer patients and clinical outcomes: a systematic review. Cancer Treatment Res Commun 21:100154CrossRefGoogle Scholar
  42. 42.
    Dabiri S, Popuri K, Cespedes Feliciano EM et al (2019) Muscle segmentation in axial computed tomography (CT) images at the lumbar (L3) and thoracic (T4) levels for body composition analysis. Comput Med Imaging Graph 75:47–55CrossRefGoogle Scholar
  43. 43.
    Popuri K, Cobzas D, Esfandiari N et al (2016) Body composition assessment in axial CT images using FEM-based automatic segmentation of skeletal muscle. IEEE Trans Med Imaging 35:512–520CrossRefGoogle Scholar
  44. 44.
    Shachar SS, Deal AM, Weinberg M et al (2017) Body composition as a predictor of toxicity in patients receiving anthracycline and taxane-based chemotherapy for early-stage breast cancer. Clin Cancer Res 23:3537–3543CrossRefGoogle Scholar
  45. 45.
    Gonzalez MC, Heymsfield SB (2017) Bioelectrical impedance analysis for diagnosing sarcopenia and cachexia: what are we really estimating? J Cachexia Sarcopenia Muscle 8:187–189CrossRefGoogle Scholar
  46. 46.
    Goodpaster BH, Thaete FL, Simoneau JA et al (1997) Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 46:1579–1585CrossRefGoogle Scholar
  47. 47.
    Miljkovic I, Cauley JA, Wang PY et al (2013) Abdominal myosteatosis is independently associated with hyperinsulinemia and insulin resistance among older men without diabetes. Obesity 21:2118–2125CrossRefGoogle Scholar
  48. 48.
    Feliciano E.C. LV, Chen W, Prado C., Shachar SS, Alexeeff S, Caan BJ: adiposity, muscle mass and delays and dose reduction on adjuvant taxane based chemotherapy for breast cancer. AACR2019 abstract:3284, 2019Google Scholar
  49. 49.
    Banerji MA, Faridi N, Atluri R et al (1999) Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 84:137–144Google Scholar
  50. 50.
    Goulart A, Malheiro N, Rios H et al (2019) Influence of visceral fat in the outcomes of colorectal cancer. Dig Surg 36:33–40CrossRefGoogle Scholar
  51. 51.
    Guiu B, Petit JM, Bonnetain F et al (2010) Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut 59:341–347CrossRefGoogle Scholar
  52. 52.
    Ebadi M, Martin L, Ghosh S et al (2017) Subcutaneous adiposity is an independent predictor of mortality in cancer patients. Br J Cancer 117:148–155CrossRefGoogle Scholar
  53. 53.
    Bradshaw PT, Cespedes Feliciano EM, Prado CM et al (2019) Adipose tissue distribution and survival among women with nonmetastatic breast cancer. Obesity 27:997–1004CrossRefGoogle Scholar
  54. 54.
    Hopanci Bicakli D, Cehreli R, Ozveren A et al (2019) Evaluation of sarcopenia, sarcopenic obesity, and phase angle in geriatric gastrointestinal cancer patients: before and after chemotherapy. Turk J Med Sci 49:583–588CrossRefGoogle Scholar
  55. 55.
    Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al (2010) Sarcopenia: european consensus on definition and diagnosis: report of the european working group on sarcopenia in older people. Age Ageing 39:412–423CrossRefGoogle Scholar
  56. 56.
    Chen LK, Liu LK, Woo J et al (2014) Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 15:95–101CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Hematology-Oncology, Lineberger Comprehensive Cancer CenterUniversity of North Carolina at Chapel HillChapel HillUSA
  2. 2.Unoeste Universidade do Oeste PaulistaPresidente PrudenteBrazil
  3. 3.Division of Hematology/OncologyUniversity of Alabama at BirminghamBirminghamUSA
  4. 4.Oncology Institute, Rambam Health Care CampusHaifaIsrael

Personalised recommendations